Figure 10.

Immediate B cell and antibody responses following SARS-CoV-2 VLP vaccination. C57BL/6 mice were immunised intramuscularly with 20 μg of either SARS-CoV-2 VLP, α-GalCer-SARS-CoV-2 VLP or SARS-CoV-2 VLP delivered with AddaVax, or PBS alone as control, at days 0 and 7. Mice were harvested on day 10. (A) Total SARS-CoV-2 specific B cells per million splenocytes, as determined by ELISpot assay. (B) SARS-CoV-2 VLP specific antibody titre, and (C) SARS-CoV-2 RBD specific antibody responses in immunised mouse sera, as measured by ELISA assay. ELISA plates were coated with VLP at 20 μg/mL or RBD at 5 μg/mL. Each point represents one animal with bars showing the mean. Endpoint titres were determined by establishing cutoff values from pre-inoculation samples. One-way ANOVA tests were used to determine statistical significance (p < 0.05, * < 0.05, ** < 0.005, *** < 0.0005, **** < 0.0001).